Table 3.
Impact of GSTM1‐null/present genotype on relapse‐free survival by stratification
| GSTM1 genotype | Log‐rank P | Adjusted HRa (95% CI) | Adjusted P | Interaction P | |
|---|---|---|---|---|---|
| Age | |||||
| ≤45 y | Null | .51 | Ref. | .414 | >.05 |
| Present | 0.78 (0.43‐1.41) | ||||
| >45 y | Null | .03 | Ref. | .013 | |
| Present | 0.52 (0.31‐0.87) | ||||
| Lymph node | |||||
| Negative | Null | .01 | Ref. | .013 | >.05 |
| Present | 0.40 (0.19‐0.82) | ||||
| Positive | Null | .50 | Ref. | .232 | |
| Present | 0.75 (0.46‐1.20) | ||||
| Size | |||||
| ≤2 cm | Null | .02 | Ref. | .019 | >.05 |
| Present | 0.45 (0.23‐0.88) | ||||
| >2 cm | Null | .32 | Ref. | .247 | |
| Present | 0.75 (0.46‐1.22) | ||||
| Chemotherapy | |||||
| No | Null | .02 | Ref. | .001 | .04 |
| Present | 0.17 (0.06‐0.50) | ||||
| Yes | Null | .32 | Ref. | .35 | |
| Present | 0.81 (0.52‐1.26) | ||||
CI, confidence interval; HR, hazard ratio.
a
Adjusted for age, lymph node status, tumor size, immunohistochemistry‐based subtype, and chemotherapy. HR with its 95% CI is calculated by the Cox risk proportion model.